Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

Enumeration and Molecular Characterization of Circulating Tumor Cells in Prostate Cancer Patients Using the GILUPI CellCollector

publication date: Nov 2, 2016
 | 
author/source: GILUPI GmbH

GILUPI GmbH announces the release of clinical data from a prostate cancer setting in August 2016.

GULUPIThe scientific paper demonstrate the isolation of circulating tumor cells (CTCs) from blood of prostate cancer patients with GILUPI CellCollector®.

Liquid biopsy - isolating and analyzing circulating tumor cells (CTCs) from the blood of prostate cancer patients - can provide additional information on prognosis of patients, treatment efficacy and molecular tumor evolution. Dr. Gerit Theil and further researcher from the Martin Luther University Halle-Wittenberg wanted to investigate the use of the GILUPI CellCollector® - in a proof of concept study. After in vivo isolation, CTCs underwent enumeration and characterization using molecular methods.

The researcher tested the functionality of the GILUPI CellCollector® in a preclinical step. They studied blood samples of 43 prostate cancer patients by applying the medical devices ex vivo.

Detection of CTCs in all tumor stages could be shown. The mean CTC count was 4.6 CTCs in patients with localized prostate cancer, 16.8 CTCs in patients with locally advanced prostate cancer, and 26.8 CTCs in patients with metastatic prostate cancer. More importantly, it could be shown that there was a significant difference in the cancer-specific survival rates. Patients with CTC counts < 5 CTCs had significant longer survival rates than patients with more than 5 CTCs. Furthermore, Theil et al. demonstrated that the captured CTCs could be characterized on a molecular level. The investigators detected tumor-associated transcripts of epidermal growth factor receptor (EGFR) and prostate-specific membrane antigen (PSMA) in patients with metastatic PCa in 42.8% and 14.3% of the analyzed samples, respectively. The above data was generated to demonstrate to the Federal Institute for Drugs and Medical devices (Germany, BfArM) the safe and effective use prior to in vivo application of the GILUPI CellCollector® in this indication. Further studies are ongoing to validate this finding as further diagnostic tool in the treatment of patients with prostate tumors.

The scientific paper entitled "The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.” by Theil et al., was published in PLoS One.


more about GILUPI


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.